Full Press Release Details
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #CARTCellTherapy--Bristol Myers Squibb Presents Results from Phase 1 Breakfree-2 Study of Zolacabtagene Autoleucel (BMS-986353) in Patients...
BMY Positive Sentiment
Bristol Myers Squibb Presents Results from Phase 1 Breakfree-2 Study of Zolacabtagene Autoleucel (BMS-986353) in Patients with Highly Active Relapsing and Progressive Forms of Multiple Sclerosis at MSToronto 2026
Key Takeaway: Bristol Myers Squibb announced positive results from the Phase 1 Breakfree-2 study of Zolacabtagene Autoleucel (BMS-986353). The study focused on patients with highly active relapsing and progressive forms of multiple sclerosis. The findings were presented at MSToronto 2026, highlighting the drug's potential efficacy.
Market Sentiment Analysis
POSITIVE FACTORS
- Bristol Myers Squibb presented promising results.
- The study targets highly active forms of multiple sclerosis.
- Zolacabtagene Autoleucel shows potential in treatment.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+17%
120-day peak, hindsight
Typical move
1.7%
average across 15 past catalysts
Lead asset
CC-95266
Phase 1 · Multiple Myeloma
Frequently Asked Questions
What is Zolacabtagene Autoleucel?
Zolacabtagene Autoleucel, also known as BMS-986353, is a CAR T-cell therapy.
What was the focus of the Breakfree-2 study?
The study targeted patients with highly active relapsing and progressive MS.
Where were the results presented?
The results were presented at MSToronto 2026.
What phase is the Breakfree-2 study?
The Breakfree-2 study is a Phase 1 clinical trial.